Literature DB >> 8193438

Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?

S C Toyama, R P Iacono.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8193438     DOI: 10.1177/106002809402800324

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


× No keyword cloud information.
  10 in total

1.  Depression in Parkinson's disease.

Authors:  H Allain; S Schuck; N Mauduit
Journal:  BMJ       Date:  2000-05-13

2.  Depression in Parkinson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 3.  Depression in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

4.  The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder.

Authors:  Lois Jessen; Lawrence J Kovalick; Albert J Azzaro
Journal:  P T       Date:  2008-04

Review 5.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 6.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

Review 7.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

8.  Initial treatment of Parkinson's disease.

Authors:  Daniel Tarsy
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.972

Review 9.  Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors.

Authors:  Abdullah Aboukarr; Mirella Giudice
Journal:  Can J Hosp Pharm       Date:  2018-06-28

10.  Rasagiline in treatment of Parkinson's disease.

Authors:  Lakshmi Nayak; Claire Henchcliffe
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.